Editing Filgrastim (section)

===Economics===
Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing [[febrile neutropenia]] depended upon the clinical situation and the financial model used to pay for treatment.<ref>{{Cite book| vauthors = Neymark N |title=Assessing the Economic Value of Anticancer Therapies  |journal=Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer |series=Recent Results in Cancer Research|date=1998|volume=148|publisher=Springer |isbn=978-3-642-72123-6|location=Berlin, Heidelberg|pages=215–219|doi=10.1007/978-3-642-72123-6|pmid=9670279|s2cid=34894897|oclc=851760173}}</ref> The longer-acting [[pegfilgrastim]] may in some cases be more cost-effective.<ref>{{Cite book| vauthors = Ellery T |title=Pharmaceutical lifecycle management : making the most of each and every brand|date=2012|publisher=John Wiley & Sons|others=Hansen, Neal.|isbn=978-1-118-26679-3|location=Hoboken, N.J.|pages=214|oclc=797824835}}</ref>